Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.54 |
| ▸ | DRD3 | P35462 | 5/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17368142 | 1.00 | DRD2 (0.54) | DRD2DRD3SIGMAR1GRM2CNR2 | |
| SCHEMBL13632659 | 0.78 | DRD2 (0.57) | DRD2DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL17364192 | 0.77 | DRD2 (0.56) | DRD2DRD3SIGMAR1 | |
| SCHEMBL20691284 | 0.74 | DRD2 (0.48) | DRD2DRD3SIGMAR1GRM2CNR2 | |
| SCHEMBL29369425 | 0.70 | DRD3 (1.00) | DRD2DRD3SIGMAR1 | |
| SCHEMBL873078 | 0.70 | DRD3 (1.00) | DRD2DRD3SIGMAR1 | |
| SCHEMBL873812 | 0.70 | DRD3 (1.00) | DRD2DRD3SIGMAR1 | |
| SCHEMBL873549 | 0.70 | DRD3 (1.00) | DRD2DRD3SIGMAR1 | |
| Bromide SCHEMBL5699015 | 0.69 | DRD3 (0.98) | DRD2DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5678691 | 0.69 | DRD3 (0.98) | DRD2DRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160470-B1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd (IL) | 2022-08-03 | — | — | EP | claimed |
| EP-4049998-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd. (IL) | 2022-08-31 | — | — | EP | disclosed |
| EP-3160470-B1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd (IL) | 2022-08-03 | — | — | EP | disclosed |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2022-01-27 | — | — | US | disclosed |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2022-01-27 | — | — | US | disclosed |
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2021-10-12 | — | — | US | disclosed |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2020-01-30 | — | — | US | disclosed |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2019-09-10 | — | — | US | disclosed |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2019-01-31 | — | — | US | disclosed |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2018-11-20 | — | — | US | disclosed |
| WO-2016003919-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-01-07 | — | — | WO | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PDE7A, PDE3A, PDE4D | DRD2 7/4885DRD3 21/4885SIGMAR1 267/4885 |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD3 5/4885SIGMAR1 12/4885 |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD3 5/4885SIGMAR1 14/4885 |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PDE3A, PDE4D, PDE9A | DRD2 14/4885DRD3 30/4885SIGMAR1 142/4885 |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD3 5/4885SIGMAR1 12/4885 |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD3 5/4885SIGMAR1 14/4885 |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD3 5/4885SIGMAR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.